H.C. Wainwright Has Just Reaffirmed $98 Target Price Per Share on Seattle Genetics (NASDAQ:SGEN) stock, While They’ve Also Reiterated Their Buy Rating

July 27, 2018 - By Vernon Prom

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

Investors sentiment increased to 1.61 in Q1 2018. Its up 0.38, from 1.23 in 2017Q4. It increased, as 24 investors sold Seattle Genetics, Inc. shares while 53 reduced holdings. 31 funds opened positions while 93 raised stakes. 159.52 million shares or 12.47% more from 141.83 million shares in 2017Q4 were reported.

Tributary Capital Mngmt Ltd Liability Corp has invested 0.11% in Seattle Genetics, Inc. (NASDAQ:SGEN). Capital Limited Ca owns 104,788 shares or 0.98% of their US portfolio. Pinnacle Assoc Ltd has invested 0.92% in Seattle Genetics, Inc. (NASDAQ:SGEN). British Columbia Mngmt Corporation holds 0.02% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 47,410 shares. Geode Management Ltd Co holds 976,886 shares or 0.02% of its portfolio. Nbt Savings Bank N A Ny reported 0.04% in Seattle Genetics, Inc. (NASDAQ:SGEN). Mariner stated it has 12,778 shares or 0.02% of all its holdings. Manufacturers Life Insurance The reported 4,663 shares or 0% of all its holdings. Switzerland-based Swiss State Bank has invested 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). Guggenheim Ltd Liability Co has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Jgp Global Gestao De Recursos Ltda invested in 0.47% or 22,334 shares. Van Eck stated it has 0.04% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). State Board Of Administration Of Florida Retirement has invested 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). Adirondack Commerce reported 100 shares stake. Earnest Prns Limited holds 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 35 shares.

Since February 1, 2018, it had 3 insider purchases, and 12 selling transactions for $266.62 million activity. BAKER BROS. ADVISORS LP had bought 3.85 million shares worth $200.00M. DRACHMAN JONATHAN G also sold $552,452 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, March 5. HIMES VAUGHN B had sold 5,000 shares worth $290,604. 9,000 shares were sold by Cline Darren S, worth $497,983 on Wednesday, May 9.

Seattle Genetics (NASDAQ:SGEN) Rating Reaffirmed

H.C. Wainwright now has a $98 TP on the $11.27 billion market cap company or 37.54 % upside potential. In a note sent to investors on 27 July, Seattle Genetics (NASDAQ:SGEN) shares have had their Buy Rating maintained by equity research analysts at H.C. Wainwright.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 8 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Seattle Genetics has $77.0 highest and $60.0 lowest target. $68.13’s average target is -4.38% below currents $71.25 stock price. Seattle Genetics had 12 analyst reports since January 31, 2018 according to SRatingsIntel. Bank of America maintained the stock with “Neutral” rating in Wednesday, February 7 report. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Overweight” rating by Morgan Stanley on Wednesday, March 21. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by Needham on Wednesday, February 7. SunTrust maintained the stock with “Hold” rating in Wednesday, February 7 report. The firm has “Buy” rating given on Thursday, February 1 by H.C. Wainwright. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given on Monday, June 11 by SunTrust. The rating was upgraded by J.P. Morgan to “Buy” on Wednesday, February 14. JP Morgan upgraded Seattle Genetics, Inc. (NASDAQ:SGEN) on Wednesday, February 14 to “Overweight” rating. As per Wednesday, February 7, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by RBC Capital Markets on Wednesday, January 31.

The stock increased 0.44% or $0.31 during the last trading session, reaching $71.25. About 655,860 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 15.50% since July 27, 2017 and is downtrending. It has underperformed by 28.07% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $11.27 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Streetinsider.com which released: “Seattle Genetics (SGEN) Adcetris On-going Launch in 1L cHL is Positive Says SunTrust.” on July 02, 2018, also Marketwatch.com with their article: “Bull ‘trend’ strengthens: S&P 500, Nasdaq reclaim the breakdown point” published on July 09, 2018, Seekingalpha.com published: “Don’t Sell Axon Enterprise – Cramer’s Lightning Round (7/11/18)” on July 12, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Seekingalpha.com and their article: “Mid-stage study underway for Seattle Genetics’ tisotumab vedotin in solid tumors; shares up 1% premarket” published on July 12, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold” with publication date: July 26, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.